Natalia Blanco

Company: Morphic Therapeutics

Job title: Associate Director - Immuno-Oncology Biology


Discussion Panel: Debating the Promise of Combinational Strategies with TGF-β 1:00 pm

Read more

day: Day Two

Integrin αvβ8 Inhibitor Improves Immune Checkpoint Therapy in Tumor Models: Illuminating Monitoring Activity in the Blood 9:30 am

Immune-checkpoint blockade (ICB) is enhanced when combined with therapies that target tumor tolerance in refractory tumors Targeting αvβ8-mediated TGF-β 1/3 pathway enhances sensitivity to checkpoint therapies in tumor models Protein or transcriptomic assessment of granzyme B may provide a useful biomarker of response to a combination of ICB and αvβ8 inhibitorsRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.